Department of Oncology, Haematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Medicine A, Hematology and Oncology, University Hospital Münster, Münster, Germany.
Ann Hematol. 2021 Nov;100(11):2727-2732. doi: 10.1007/s00277-021-04601-0. Epub 2021 Jul 31.
Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody-drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities.
治疗复发或难治性 B 淋巴细胞白血病（r/r B-ALL）的选择有限，这些患者的预后仍然不容乐观，但新型免疫治疗选择，如抗 CD22 抗体药物偶联物 Inotuzumab-Ozogamicin（InO），已改善了这些患者的预后。在开始抗原导向的免疫治疗之前，流式细胞术对于评估抗原表达至关重要。在这里，我们介绍了 3 例成人 r/r B-ALL 患者的流式细胞术和临床数据，这些患者在接受 InO 治疗后出现抗原表达减少或丢失而治疗失败。此外，我们还介绍了两种不同的诊断性 CD22 特异性抗体克隆的比较数据，它们在染色强度上存在显著差异。
